Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

8 days required by the inclusion criteria.

A total of 87 percent of patients in the placebo group completed treatment, as did 82 percent, 77 percent, and 62 percent in the 200, 400, and 600 mg/day Vimpat(R) groups.

Summary of Vimpat(R) Data Presented at 2008 AES Annual Meeting

Early Onset of Efficacy in the Initial Weeks of Treatment with Lacosamide: A Pooled Analysis of Three Phase II/III Trials

This analysis found that Vimpat(R) demonstrated statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day.

-- At the end of the first week of treatment in this study, when all participants in the active treatment groups were receiving 100 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (33.0 percent Vimpat(R) group vs. 19.4 percent placebo; p<.01). Also during the first week, 39.1 percent of patients treated with Vimpat(R) experienced a 50 percent or greater reduction in seizures, compared with 31.3 percent in the placebo group (p<.01).

-- By the end of the second week of treatment, when all participants in the treatment groups were receiving 200 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 percent placebo; p<.01). The percentage of patients with a 50 percent or greater reduction in seizure frequency was 40.2% for patients receiving Vimpat(R) and 32.2 percent for placebo (p<.01 vs. placebo).

-- These significant seizure reductions appeared to be maintained over subsequent weeks of Vimpat(R) treatment.


    Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.256)
    Michael Sperling, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty,
     PhD
    Thomas Jefferson Universit
'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... SAN DIEGO, July 24, 2008 NuVasive, Inc.,(Nasdaq: ... on developing products for,minimally disruptive surgical treatments for ... previously announced acquisition of the Osteocel,biologics business from ... $35,million in cash, plus additional milestone-based contingent payments ...
... Calif., July 24 Abaxis, Inc.,(Nasdaq: ABAX ), a ... results for the first,fiscal quarter ended June 30, 2008., ... up 7% over last year,s comparable quarter. -- Total ... 127 units or 19% over last ...
... physicians, pulmonary and critical care clinicians, ... overuse of antibiotics, DURHAM, N.C., July 24 ... of the American Thoracic Society and,Society of Hospital ... physicians, and researchers are unanimous in their view ...
Cached Biology Technology:NuVasive Completes Acquisition of Osteocel Biologics Business 2NuVasive Completes Acquisition of Osteocel Biologics Business 3NuVasive Completes Acquisition of Osteocel Biologics Business 4NuVasive Completes Acquisition of Osteocel Biologics Business 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 8U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Oct. 16, 2012  Today 23andMe, the leading personal ... as Vice President Communications, Neil Rothstein as Vice ... Strategic Alliances joining the company,s executive leadership team. ... Castro is responsible for the company,s corporate communications, ...
... MedNet Solutions, a global life sciences technology solutions ... & Data Corporation (SDC), a specialized Contract Research Organization ... services to the life sciences industry, are pleased to ... ™ EDC platform as their eClinical ...
... MOUNTAIN VIEW, Calif. and RAANANA, Israel, Oct. 23, ... ), the leading licensor of silicon intellectual property ... Ltd, a global supplier of embedded speech processing ... deliver enhanced speech processing solutions for smart devices, ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 2Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner 3CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 2CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs 3
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... for 10 separate biopanning experiments, complexity ... gIII Sequencing Primer (100 pmol), for ... Primer (100 pmol), for automated DNA ... Control target (Streptavidin) and Elutant (Biotin), ...
... Materials for 15-20 enhancements when used as ... Blot Signal Enhancement System is designed to amplify the ... excellent tool for evaluating proteins with low expression., ... membrane prior to blocking the membrane; 1x solution; 250 ...
Biology Products: